Skip to main content

Morton's Neuroma

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Centrexion Therapeutics
2 programs
1
1
CNTX-4975Phase 21 trial
CTNX-4975Phase 11 trial
Active Trials
NCT02550756Completed11
NCT02678793Completed67Est. Mar 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
XylocainePhase 11 trial
Active Trials
NCT01298310Completed27Est. May 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Centrexion TherapeuticsCNTX-4975
Centrexion TherapeuticsCTNX-4975
AstraZenecaXylocaine

Clinical Trials (3)

Total enrollment: 105 patients across 3 trials

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Start: Dec 2015Est. completion: Mar 201767 patients
Phase 2Completed

Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

Start: Feb 201411 patients
Phase 1Completed

A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)

Start: Feb 2011Est. completion: May 201227 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.